NCCN Foundation Announces Awards for Rising Cancer Research Leaders
National Comprehensive Cancer Network s Oncology Research Program to oversee projects from early-career investigators advancing key areas for study in cancer care, such as cancer prevention, racial disparities in screening, immunotherapy, new insights in radiotherapy, and CAR T-cell therapy.
News provided by
Share this article
® today announced six new recipients for the 2021 NCCN Foundation Young Investigator Awards (YIA) Program. The honorees will receive up to $150,000 in funding, over two years, to advance important research on important issues in oncology. These early-career investigators from NCCN Member Institutions represent tomorrow s leaders for advancing cancer care. The NCCN Oncology Research Program (ORP) managed the selection process and will provide guidance and oversight for the projects over the grant duration.
NCCN Foundation announces awards for rising cancer research leaders eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology
NCCN Oncology Research Program to oversee projects exploring oral medication combination targeting tumor suppression genes.
News provided by
Share this article
®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and cedazuridine (100 mg). The NCCN ORP convened a Scientific Review Committee to review, evaluate, and select awardees and will provide oversight for the two-year studies which will commence later in 2021. Research funding will be provided by a grant from Taiho Oncology, who will also supply the decitabine and cedazuridine tablet.
Share this article
PLYMOUTH MEETING, Pa., April 13, 2021 /PRNewswire/ The April 2021 issue of
JNCCN Journal of the National Comprehensive Cancer Network publishes new research from Memorial Sloan Kettering Cancer Center (MSK) and Gustave Roussy Institute, which suggests that baseline brain imaging should be considered in most patients with metastatic kidney cancer. The researchers studied 1,689 patients with metastatic renal cell carcinoma (mRCC) who had been considered for clinical trial participation at either of the two institutions between 2001 and 2019 and had undergone brain imaging in this context, without clinical suspicion for brain involvement. The researchers discovered 4% had asymptomatic brain metastases in this setting. This group was found to have a low median 1-year overall survival rate (48%), and median overall survival (10.3 months).
JNCCN Study: Important potential role for routine brain imaging in advanced kidney cancer eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.